Telix Pharmaceuticals Ltd. ADR (TLX) saw downtrend of -16.12% in the recent trading with $10.15 being its most recent. The current price level -66.57% lower than the highest price of $30.36 marked by the stock while trading over the past 52-weeks, whereas it is -3.33% higher than the lowest price of $10.50 the company dropped to over past 52-weeks. The latest news story on TLX appeared in (GlobeNewswire) under the title “Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference”.
Squeezing the time span to 30 day period shows us the stock is currently trading -28.87% below one month high and is +3.57% above of the lowest during that time. Looking into the simple moving average, Telix Pharmaceuticals Ltd. ADR (TLX)’s stock stands at a SMA-50 of $14.08 while that of 5-day is reading $11.89.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.38 for the stock.
Telix Pharmaceuticals Ltd. ADR Earnings – What Happened With TLX
Coming around sales and income figures on TLX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
TLX – Telix Pharmaceuticals Ltd. ADR Stock Earnings Estimates
The perspective of Telix Pharmaceuticals Ltd. ADR (NASDAQ:TLX)’s current quarter earnings identifies that analysts are in consensus over the estimate of 0.21 for stock’s EPS in the current quarter.
Telix Pharmaceuticals Ltd. ADR – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 334.13 million. TLX does have institutional investors; and they hold 0.13% of the stock.
Key Metrics forTLX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Telix Pharmaceuticals Ltd. ADR has a debt to equity ratio of 0.99.
